NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
NCT06737250
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
33
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary CNS Lymphoma (PCNSL)
Interventions
DRUG:
R2P -> RP
Sponsor
NOBO Medicine